ABSTRACT
BACKGROUND
Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of morbidity and mortality worldwide. 1 According to the World Health Organization approximately 65 million people are living with moderate to severe COPD. India and China constitute 33% of the total human population and account for 66% of the global COPD mortality. 2, 3 Further, it has been estimated that COPD associated mortality is likely to grow by 160% in the Southeast Asian region in the coming decades.
Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) is defined as "An acute worsening of respiratory symptoms that result in additional therapy". 4 Acute Exacerbation of COPD (AECOPD) is common cause for hospital admission in COPD patients. AECOPD causes negative impact on hospital stay, treatment, readmission and diseases progression. 4, 5, 6 In stable COPD, prognostic indices have been thoroughly investigated and tools predicting mortality risk, such as the BODE Score, are well established. 7 However, prognostic research in exacerbations requiring hospitalisation has been limited. The DECAF SCORE (Dyspnoea, Eosinopenia, Consolidation, Acidaemia, and atrial Fibrillation score) is a severity scoring system applied to patients of AECOPD. (DECAF) score was first introduced by Steer et al. 8 DECAF showed strong performance and good correlation with clinical outcome in majority of studies. 8, 9, 10 The present study conducted to study the utilisation of DECAF score in predicting in hospital outcome in patients with acute exacerbation of chronic obstructive pulmonary disease.
MATERIALS AND METHODS
Patients admitted in K.R Hospital with AECOPD were recruited between the May 2017 and July 2017. Approval was granted by the Ethical Committee of Mysore Medical College and Research Institute. A pretested proforma meeting the objective of the study was prepared for collection of data. The subjects of the study are selected in accordance with inclusion and exclusion criteria, the purpose of the study is explained to the patients and informed consent is obtained.
Inclusion criteria encompassed known cases of COPD patients with acute exacerbation, patients with clinically probable indicators of COPD with acute exacerbation, patients who meets the GOLD criteria for diagnosis of COPD with exacerbation. Patients who were excluded from the study were patients with known case of asthma, COPD patients with ischemic heart disease, patients with neuromuscular disease, patients with restrictive lung disease.
Data Collection-Data is collected through a preformed proforma from each patient. Consent of the patient and or guardian was taken. Qualifying patients were subjected for a detailed history, clinical examination and relevant biochemical investigations. A thorough clinical examination was carried out with particular reference to vital parameters, respiratory system, cardiovascular system and other parameters as per prescribed proforma. DECAF score was applied to all study subjects and the severity of AECOPD is graded at the time of admission. Dyspnoea was graded according to the extended Medical Research Council Score (eMRCD), patients unable to leave the house without assistance due to breathlessness were divided into eMRCD 5a and 5b based on ability to wash and undress independently and the inability to do so respectively. Where necessary, blood was collected on admission for arterial blood gas analysis. Atrial fibrillation was confirmed with ECG, consolidation was noted from chest X-ray. Complete blood picture was noted for presence of eosinopenia. Patients managed according to their condition and current hospital protocols. For in-hospital outcome, the total duration of hospital stay, need of assisted ventilation and in hospital deaths were noted. Once patient was recovered from acute exacerbation patient has been discharged from hospital with maintenance therapy for COPD .Discharge of patient has been considered as positive outcome in our study. DECAF Score. 
RESULTS
Total 80 patients were recruited and entered in the study. Mean age of males was 66.5 years whereas mean age for females was 70.9 years ( Table 2 ). Age distribution of our study population is given in Table 3 . A majority of patients 33.8% had a total DECAF score of 2 points while the maximum DECAF score was 5 points which was seen in only 3.8% of subjects. Overall 58.8% of patients had eMRCD score of 5b. Eosinopenia was seen in only 12 subjects (15%). Evidence of consolidation was seen in 32 subjects (40%). Only 16 patients had acidaemia (20%) and 8 patients had atrial fibrillation (10%). Out of eighty patients six patients are withdrawn from the study.
The need for invasive ventilation raised linearly with the DECAF score as well as the in-hospital deaths. Majority of patients with DECAF score of 1 were managed with bronchodilators and discharged after a mean of 3 days. Of the 33.8% of patients with DECAF score of 2 70.4% required inhalations oxygen, remaining 29.6% were managed with only bronchodilators, average hospital stay was 6 days. Patients with DECAF score of 3 had an average hospital stay of 10 days with 66.7% requiring inhalational oxygen and remaining 33.3% required NIV ventilation. Whereas patients with DECAF score of 4 or more had an average of 15 days hospital stay. The length of hospital increases with increase in decaf score (Figure 1 ). 46.2% of patients with DECAF score of 4 died, whereas only 38.5% were discharged for the same score, Of the total 16.3% of patients with DECAF score of 4, 15.8% required inhalational oxygen while 53.8% required NIV ventilation and remaining 30.8% required mechanical ventilation following intubation (Table 4) . Of the 3.8% of patients with DECAF score of 5 (max score in our study group) there was a 100% initiation of assisted ventilation 33.3% received NIV ventilation while 66.6% required endotracheal intubation with ventilator support. In present study 85 percent patients were survived. Total 6 patients (7.5%) had died, belonging to high risk DECAF group (Score 3 to 6) ( Table 5) . Patients who are in low and moderate risk group had good outcome. 9 showed that dyspnoea was the most common presentation for exacerbations of COPD which is comparable to present study. Most of the studies.
9,10,13,14 of AECOPD reports mortality rate between 4 to 30%, present study has the mortality rate of 7.5%.
Steer et al 9 observed that Low (0-1 DECAF point) risk group has in-hospital mortality 1.4%, Intermediate (2 DECAF points) group had in-hospital mortality 8.4% and High (3-6 DECAF points) group had in-hospital mortality 34.6%. In present study mortality was seen only in high risk DECAF group. Studies done by Wildmann MJ et al 12 , R.K Yadavlli et al. 15 Observed that patients with high DECAF score requires assisted ventilation compared to lower scores, this findings are comparable to present studies. R.K. Yadavilli et al 15 reported that length of hospital stay was more in patients with DECAF score of more than 3. Study done by R.K. Yadavalli et al 15 included total 78 patients, among them 66 were survived and 12 patients died. Average Length of Stay in hospital was 15.1 days. Length of stay was highest in those with DECAF scores of 3-5 (16.7 days) and lowest in those with scores of 0-1 (12 days). This finding is consistent with present study. R. Nafea et al. 11 carried out a study on 200 AECOPD patients, they illustrated that the DECAF score showed an excellent discrimination for in-hospital mortality. Based on our study population the DECAF score provided a linear correlation between hospital stay and in-hospital deaths. Patients divided according to the DECAF score severity were able to Table 4 . Treatment among Study Populations in Relation to Decaf Score receive optimum treatment based on their level of exacerbation. With the use of the DECAF score patients were able to be shifted to for intensive care treatment and assisted ventilation on a timely manner.
CONCLUSION DECAF score provided a fast, simple and effective tool to triage patients to receive the appropriate level of care for their needs. In conclusion the DECAF score can easily be incorporated at the time of admissions for acute exacerbations of COPD, and can be used as a reliable tool to guide the management and in deciding the time of discharges appropriately.
